account_circleRecruiting

Advanced solid tumors harboring KRAS G12C mutation

Bayer Identifier:

22676

ClinicalTrials.gov Identifier:

NCT06659341

EudraCT Number:

Not Available

EU CT Number:

2024-513300-34-00
A phase I study of BAY3498264 given together with sotorasib in participants who have advanced solid cancers with specific genetic changes called KRASG12C mutation

Trial purpose

Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation.

Sotorasib is a drug that targets cancer cells which contain mutated KRASG12C protein; it can stop the cancer cells from growing and can lead to their death. Sotorasib is already approved to be used by doctors. However, when sotorasib works, it normally only works for a period of time, after which the cancer starts to grow again, and the patient may need a different treatment.

BAY3498264 is a drug that is currently under development. It is expected to prevent the activity of a protein called son of sevenless 1 (SOS1). The SOS1 protein works together with KRAS; by blocking the activity of SOS1 with BAY3498264, it is hoped that the benefit offered by treatment with sotorasib may be increased – for example, resulting in a longer or deeper response.

The main purpose of this first-in-human study is to learn how safe BAY3498264 is when given together with sotorasib and what is the maximum dose of BAY3498264 that can be safely given to participants together with sotorasib.

During the study, participants will receive the following treatments:
•   BAY3498264: participants will first receive BAY3498264 alone for seven days and then BAY3498264 in combination with sotorasib. These combination treatments will be given in cycles, each lasting 21 days.
•   Sotorasib: participants will receive a standard, approved dose of Sotorasib once every day with BAY3498264.

The treatment will continue for as long as participants benefit from it without any severe medical problems or until they or their doctor decide to stop the treatment, or until their cancer starts to grow again despite the treatment (also called ‘progression’).
This study has 3 parts, the dose escalation part, the backfill part and the expansion part.

During the study, researchers will collect blood, urine, and take imaging scans like CT, PET, MRI, and X-rays, and examine the participants’ heart health using an electrocardiogram (ECG). Participants’ health is monitored throughout the study.

Key Participants Requirements

Sex

All

Age

18 - N/A
  • - Histologically confirmed solid tumor malignancy with documented KRASG12C mutation as assessed by an appropriately accredited laboratory.
    - Documented disease progression after treatment with at least 1 prior standard of care (SoC) systemic therapy other than a G12C inhibitor for locally advanced or metastatic disease, and with no further standard treatment options available, or when standard treatment options are not acceptable and this study is a reasonable option.
     -- Participants whose access to SoC therapies is limited due to regional access, refusal, intolerance, or eligibility may participate.
     -- Prior G12C inhibitor treatment is permitted. Participants receiving prior G12C inhibitor therapy must have documented disease progression after treatment, or have discontinued that treatment due to intolerance.
    - Adequate archival formalin-fixed paraffin-embedded tumor tissue available (preferably no older than 6 months, obtained after the last targeted therapy). If archival material is not available, a fresh tumor biopsy should ideally be obtained if safe and feasible.
    - Eastern Cooperative Oncology Group (ECOG) of 0 to 2 and life expectancy of at least 12 weeks.
  • - Active central nervous system (CNS) tumors including metastatic brain disease, at the time of screening.
    a. ‘Active’ is defined as untreated brain lesions (new or progressing) or symptomatic brain lesions (as determined by the investigator)
    b. Participants who have received treatment (e.g. surgery or radiotherapy) for brain metastases ending at least 4 weeks before cycle 1 day 1 (C1D1) may be eligible if, at the point of study entry:
    i. their condition is considered stable by the investigator
    ii. they have no residual neurological symptoms (Grade >2)
    iii. a follow-up Magnetic resonance imaging (MRI) scan during the screening period shows no progression or new lesions
    iv. they do not need systemic corticosteroids to treat symptoms of brain metastasis
    - Any grade active pneumonitis or interstitial lung disease (ILD), or past medical history of:
    a. Grade ≥2 ILD,
    b. Drug-induced ILD
    c. Radiation pneumonitis that required steroid treatment within the last 12 months
    - Additional malignancy within the past 3 years, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, in agreement with the Sponsor, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.
    - Any positive test result for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating the presence of virus.
     -- Active HBV (chronic or acute; defined as having a known positive HBsAg test at the time of screening) except for participants on antiviral therapy for HBV with an undetectable or low viral load.
     -- Participants with past HBV infection or resolved HBV infection (defined as the presence of HBcAb and absence of HBsAg) are eligible if HBV DNA is negative.
     -- Participants positive for HCV antibody unless polymerase chain reaction is negative for HCV RNA. Any prior antiviral therapy must be completed at least 28 days before the first dose of study intervention.

Trial summary

Enrollment Goal
104
Trial Dates
November 2024 - November 2027
Phase
Phase 1
Could I Receive a placebo
No
Products
BAY3498264
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Recruiting
Rigshospitalet - KræftbehandlingCopenhagen OE, 2100, Denmark
Recruiting
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - SuttonSutton, SM2 5PT, United Kingdom
Recruiting
The Christie NHS Foundation Trust - Christie HospitalManchester, M20 4BX, United Kingdom
Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia MedicaRoma, 00168, Italy
Recruiting
Gruppo Humanitas - Humanitas Research Hospital - Cancer Centerrozzano, 20089, Italy
Not yet recruiting
Institut Català d'Oncologia HospitaletL Hospitalet de Llobregat, 8907, Spain
Not yet recruiting
Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO)Barcelona, 8035, Spain
Recruiting
Macquarie University HospitalMacquarie Park, 2109, Australia
Recruiting
Peninsula and Southeast OncologyFrankston, 3199, Australia
Not yet recruiting
Border Medical oncology - Albury Wodonga Regional Cancer CentreAlbury, 2640, Australia

Primary Outcome

  • Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) categorized by severity.
    date_rangeTime Frame:
    30-35 days after the last dose
  • Maximum tolerated dose (MTD) or Maximum administered dose (MAD) of BAY 3498264 in combination with sotorasib.
    date_rangeTime Frame:
    Approximate 3 years
  • Number of participants with Dose-limiting toxicity (DLTs) during the DLT observation period categorized by severity.
    date_rangeTime Frame:
    DLT evaluation period (Cycle 1) includes 28 days
  • Maximum observed drug concentration in plasma (Cmax) of the respective dosing interval of BAY3498264 after single dose and multiple dose administrations.
    date_rangeTime Frame:
    Multiple time points: Cycle 1 28-day cycle followed by 21-day treatment cycles
  • Area under the concentration vs. time curve (AUC) of the respective dosing interval of BAY3498264 after single dose and multiple dose administrations.
    date_rangeTime Frame:
    Multiple time points: Cycle 1 28-day cycle followed by 21-day treatment cycles

Secondary Outcome

  • Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by investigator assessment.
    date_rangeTime Frame:
    Every 6 weeks (±7 days) for the first 36 weeks and every 9 weeks (± 7 days) thereafter until radiological disease progression (PD) occurs
  • Recommended dose(s) and schedule(s) of BAY 3498264 to be used in combination with sotorasib for further development stages.
    date_rangeTime Frame:
    Approximate 3 years

Trial design

Phase 1 study of a SOS1 inhibitor, BAY 3498264, in combination in participants with advanced KRASG12C-mutated solid tumors
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Non-randomized
Blinding
N/A
Assignment
Sequential Assignment
Trial Arms
3